The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

We report a case in which a renal transplant recipient with metastatic melanoma had an excellent response to treatment with second line programmed cell death protein 1 (PD-1) inhibitor therapy, pembrolizumab. Acute cellular allograft rejection on initiation of PD-1 inhibitor was successfully reversed with methylprednisolone. By converting the patient to sirolimus and giving predose prednisolone, pembrolizumab was continued with stable renal function and an excellent oncological response. This case supports the efficacy of PD-1 inhibitors in patients who are chronically immunosuppressed, and suggests an approach to maintain transplant function.

Related Products

Cat.No. Product Name Information
S1039 Rapamycin (AY-22989) Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804,AY-22989) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Related Targets

mTOR Autophagy